Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

Publication | Closed Access

DOI

109

Citations

References

2010

Year

Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève, Étienne Brain, Jean‐Pascal Machiels, Jean‐Charles Soria, Stefan Sleijfer, Pascal Wolter, Isabelle Ray‐Coquard, Christel Fontaine,

European Journal of Cancer

OncologyMedicinePathologyImmune Checkpoint InhibitorBreast CancerAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchPolo-like Kinase 1Inhibitor Bi 2536